* Viveve Medical Inc VIVE.OQ VIVE.O is expected to show
a rise
in quarterly revenue when it reports results on November 10.
* The Englewood Colorado-based company is expected to
report a
5.5% increase in revenue to $1.705 million from $1.62 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Viveve Medical Inc
is for
a loss of 66 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Viveve
Medical
Inc is $4.68, above its last closing price of $0.54.
This summary was machine generated November 9 at 03:01 GMT. All
figures in US dollars unless otherwise stated